Emergent BioSolutions Inc expected to post earnings of 44 cents a share - Earnings Preview

Emergent BioSolutions

05/05/2025 22:09

Emergent BioSolutions Inc EBS.N, EBS is expected to show a fall in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The Gaithersburg Maryland-based  company is expected to report a 27.1% decrease in revenue to $219 million from $300.4 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on March 3 2025, for the period ended March 31, was for revenue between $200.00 million and $240.00 million. (Sales/Revenue majority basis is on Total Revenue.)

​LSEG's mean analyst estimate for Emergent BioSolutions Inc is for earnings of 44 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50​, above​ its last closing price of $5.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.50
-0.49
0.05
Beat
110.1
Sep. 30 2024
0.13
0.14
1.37
Beat
878.6
Jun. 30 2024
-0.94
-0.94
-2.32
Missed
-145.5​
Mar. 31 2024
-0.87
-0.86
0.59
Beat
168.6
​​Dec. 31 2023
-0.14
-0.19
-0.77
Missed
-305.3
Sep. 30 2023
-0.25
-0.22
-0.48
Missed
-114.9​
Jun. 30 2023
-0.53
-0.49
-1.06
Missed
-117.8
Mar. 31 2023
-1.22
-1.24
-3.17
Missed
-155.6

This summary was machine generated May 5 at 21:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)